LGR5 and glioma: Furthermore, downregulation of LGR5 in FP (log2FoldChange = −4.56, padj = 1.03 × 10−9) may also demonstrate evidence of an anti-tumor response through regulation of the Wnt/β-catenin signaling pathway, as increased expression of LGR5 is associated with poor prognosis in glioma (70), breast cancer (71) and oral squamous cell carcinoma (72).